The formulation of sublingual tablets of Ondansetron HCl was carried out by using direct compression technique and evaluation tests were carried out as per pharmacopoeial specifications. Poor compressibility problem of Mannitol was overcome by coprocessing it with maltose and corn starch in varying ratios. The results of evaluation tests indicate that the ratio of Mannitol: Maltose: Corn starch: 19:2:1 gave better tableting performance with respect to precompression & postcompression parameters. It was also observed that increase in maltose content, increased the hardness but negatively affects disintegration and drug release and vice versa. Furthermore the study on effect of superdisintgrants shows that Crospovidone gives faster disintegration and satisfactory drug release in concentration of 4% compared to that of Sodium starch glycolate & Croscarmelose sodium. Formulation using a bioadhesive polymer PVP K 30 in ratio of 0.5% showed uniform release of drug over a period of 20 minutes with complete solubilization of tablet compared to that of gelatin and carbopol 934. On numerical optimization of prepared formulations, three formulations were suggested by Design Expert 8.0.7.1(Trial Version), among that Formulation B gave better correlation between predicted value and observed value. Thus Formulation B was chosen as global best formulation.
INTRODUCTION
Vomiting is the reflex action of ejecting contents of stomach through the mouth and sometimes through the nose, while nausea is the feeling that one is about to vomit. The act of emesis and sensation of nausea occurs due to a variety of reasons like ingestion of drugs, gastric irritant, chemotherapy, radiotherapy GI infections. 1 Vomiting occurs due to stimulation of the emetic center (Chemoreceptor Trigger Zone) at medulla oblongata. Nausea is accompanied by reduced gastric tone.
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Ondansetron is a highly selective 5-HT 3 receptor antagonist and numerous studies have demonstrated its superior antiemetic efficacy in prevention of nausea and vom- iting. Until, now only intravenous and oral formulations of 5HT 3 receptor antagonists were available. Recently a new formulation of a 5HT 3 receptor antagonists in the form of suppositories, nasal drug delivery formulations, transdermal drug delivery systems have been developed. 3, 4 The intravenous formulation is suitable for in-patient, but it is not ideal in ambulatory conditions. The oral dosage form is not appropriate for all patients, in particular for individuals with difficulty in swallowing or those with poorly controlled nausea or vomiting. 5 Transdermal or nasal formulations though have number of advantages over oral or parenteral route, difficulties in formulation & high cost of manufacturing make it nonviable. To over-come these problems oral mucosa can be used as an alternative route for administration of antiemetic drugs. Drug absorption through a oral mucosa is generally efficient due to absence of the stratum corneum epidermis. Mucosal surfaces are rich in blood supply, providing the means for rapid drug transport directly into the systemic circulation. Oral transmucosal administration also bypasses the enterohepatic circulation and prevents immediate destruction of therapeutic agent by gastric acid or first-pass effects of hepatic metabolism. 6 Oromucosal drug delivery can be categorized into sublingual, buccal, palletal and gingival. The sublingual mucosa is more permeable & show faster onset of action compared to other oromucosal routes. 7 Sublingual route refers to a method of administering therapeutic substances through the floor of mouth in such a way that the substances are rapidly absorbed through the rich vasculature that exists under the tongue rather than through the digestive tract, which allows the drug substances a more direct contact with the blood circulation, thus providing fast onset of action.
8 Although various sublingual formulations are available, tablet formulation is the most preferred dosage form.
9 Sublingual tablets containing soluble ingredients get dissolved in a specified time without causing any discomfort. Direct compression is simplest method of tablet manufacture as it required less equipments, has minimum processing steps, reduced labor cost. It is a dry process hence deterioration of active ingredient has been prevented. Further advantage of direct compression is that tablets disintegrate into their primary particles rather than granular aggregates. The resultant increase in surface area available for dissolution results in faster drug release. 10 The direct-compression process is highly influenced by powder characteristics such as flowability, compressibility, and dilution potential. Difficulty in getting suitable excipients with high functionality creates opportunities for the formulation scientists to develop newer grades of existing excipients. Developing newer grades of existing excipients with varying physicochemical properties has been carried out by using techniques referred as "Coprocessing" or "Particle Engineering" of excipients. Co-processing is a novel phenomenon of developing a new single-bodied excipient by interacting two or more excipients at sub-particle level with an objective to provide a synergy of functionality improvement as well as masking of the undesirable properties of individual excipients. A combination of plastic & brittle materials is necessary in order to have an optimum tableting performance.
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MATERIALS AND METHODS
Ondansetron Hydrochloride supplied as a gift sample by Samartha Lifesciences Pvt Ltd. Mannitol, Maltose, Corn Starch, PVP K30, Carbopol 394 and Gelatin were purchesed from Himedia labs, Mumbai. Super-disintegrants (Crospovidone, Croscarmelose sodium and Sodium starch glycolate) were purchased from Yarrow chemicals, Mumbai.
Selection of Excipients for Coprocessing:
Mannitol is mostly used as a diluent for the direct compression. But it is a poorly compressible saccharide with high hygroscopic nature. This may cause difficulties in tableting performance leading to poor mechanical strength, andunsatisfactory flow characteristics. According to scientific literatures, combination of poorly compressible saccharides and highly compressible saccharides gives a good mechanical strength. Maltose is high compressible saccharide usually used in the preparation of chewable tablets. Combining mannitol & maltose gives better hardness to the formulation. Flowability, compressibility of a formulation could be improved by Coprocessing of a brittle material with a fibrous material. Starch is the most widely used filler/ binder in tablet formulations, generally it is used in a concentration of 5-25% w/w as binder & 3-15% w/w as tablet disintegrant. Thus in the present work Mannitol was co-processed with maltose & corn starch and used as diluent for the preparation of sublingual tablets of Ondansetron HCl.
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Coprocessing of mannitol
Physical mixtures of mannitol and corn starch were prepared in different ratios as mentioned in the (Table  1) . Maltose was dissolved in specified quantity of distilled water. The prepared maltose solution was added to mannitol-corn starch mixture with constant stirring at 200 rpm using magnetic stirrer. Stirring was continued up to 30 minutes. The resultant mixture was kept in a refrigerator overnight & then dried at 70 0 C. The dried mass obtained was ground & passed through sieve No. 44 to obtain fine granules. 15 Angle of repose of powder blend was determined by the funnel method. The accurately weighed powder blend was allowed to flow through the funnel freely on to the surface. The diameter of the powder cone was measured and angle of repose was calculated using the equation θ = Tan -1 h/r.
Density of powder 16
A powder blend from each formulation was introduced in to a 10 ml glass measuring cylinder. The initial volume and weight was noted. The cylinder was tapped 50 times on to a hard surface from a height of 2.5 cm at an interval of one second. Tapped volume was noted. Based upon the data obtained Untapped Bulk Density and Tapped Bulk Density were calculated.
Compressibility Index and Hausner's Ratio 16
Compressibility Index and Hausner Ratio of powder blend was determined by using Tapped bulk density and untapped bulk density. Evaluation of tablets for Post compression studies:
A diametric compression test was performed according to European Pharmacopoeial method 2.9.8 using Monsanto Hardness Tester. According to standard literature in case of sublingual tablet hardness of 2 kg/cm 2 was acceptable.
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Friability 19
The friability test was performed according to the IP guidelines. Since the tablet weight (125 mg) was always less than 650 mg, a random sample of whole tablets corresponding to 6.5 g was dedusted, accurately weighed, and placed in the drum of a Roche Friability tester (Mfg by Koshiash Industries). Drum was rotated 100 times and tablets were removed, dedusted, and accurately weighed. A maximum weight loss of not more than 1.0% was considered acceptable.
Uniformity of weight 19
As per IP guidelines to perform test for uniformity of weight 20 tablets from each batch were selected randomly and their average weights were calculated using a digital weighing balance (Essae Teraoka ltd). Percentage weight difference was calculated and checked with IP specifications.
Wetting time 20 The test for wetting time was carried out by using two layers of a rectangular absorbent paper (11 cm x 7.5 cm) fitted into a Petri dish & wetted thoroughly with distilled water. The tablet was placed at the center of the plastic dish and the time required for the water to diffuse from the wetted absorbent paper throughout the entire tablet was recorded using a stopwatch.
Determination of drug content
21, 22
Twenty tablets from each formulation were weighed and powdered. 10 mg of the powder was weighed accurately and dissolved in 100 ml of distilled water. The mixture was sonicated (Equitron) for 180 seconds and filtered through Whatman filter paper No. 40. The filtrate was further diluted with distilled water and absorbance was measured at 310 nm. By using slope of standard calibration curve the amount of Ondansetron HCl was calculated.
Disintegration Test 15
Disintegration test was carried out according to USP NF standard. One tablet was placed in each of the six tubes and the using distilled water maintained at 37 0 C ± 2 0 C and the tablets were observed for disintegration. At the end of the time limit i.e. 2 minute as directed for sublingual tablet, the basket from the fluid was lifted up and observed for the tablets complete disintegration.
In-vitro drug release profile 23 In vitro drug release studies were carried out by adopting Modified European Pharmacopoeial method by using distilled water as dissolution medium at 37 0 C ± 0.5 0 C with at 50 rpm (paddle). Samples were collected at 2, 4, 6, 10, 15 & 20 minutes intervals. The amount of Ondansetron HCl released was estimated at 310 nm using UV spectrophotometer (Lab India 3000 + ). The cumulative percentage of drug release was calculated and the data obtained was presented in the dissolution rate profiles as a function of time in (Table 3) . According to the scientific literature, the amount of drug released from sublingual tablets must exceed 80% of its total content with in 15 minutes.
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In-vitro Drug release kinetics 25, 26 The prepared sublingual tablets of Ondansetron HCl were subjected in vitro drug release kinetic studies. To 
RESULTS AND DISCUSSIONS
Coprocessing of mannitol with maltose and Corn Starch in varying ratios was carried out and it was compared with their physical blend (formulations F5 & F12). The result obtained showsed that coprocessing of excipient improves the tableting characteristics of excipient and gives out a tablet with better hardness, reduced friability & satisfactory in vitro drug release. Along with this coprocessing also improves precompression characteristics as better flow property, bulk density to near about 0.5 w/v which is desirable for a sublingual tablet. The tablets prepared using unprocessed physical blends fail flowability test and in case friability test chipping of tablets was observed. But tablets prepared by using coprocessed excipients with equal concentrations of other excipient showed a satisfactory flow, better hardness and a uniform in vitro drug release. Hardness of tablet Type of superdisintegrants and their ratios mainly affects the disintegration time and indirectly also affects Dissolution rate of the tablet. By comparing Formulations F5, F6, F7 it was found that tablets containing Crospovidone showed faster disintegration compared to that of tablets containing Ac-Di-Sol & Sodium starch glycolate. Ac-Di-Sol though gave better result than that of Sodium starch glycolate, but in comparison with Crospovidone it showed slower disintegration and higher wetting time. By comparing formulations F2 and F4 it was also found that, the increase in concentration of superdisintegrant reduced disintegration time and resulted in faster disingration.
To ensure a more intimate contact of sublingual dosage form the bioadhesive polymers can be employed which posses strong bioadhesive/ mucoadhesive properties. Increasing the contact time with the sublingual mucosa with a mucoadhesive polymer improves sublingual bioavailability and result in more predictable plasma levels of the drug, leading to better therapeutic efficacy and reproducibility. The concentration and type of mucoadhesive polymer employed has significant influence on release and absorption of drug from sublingual tablet dosage form. By comparing Formulation F5, F10 and F11 it was observed that addition of a bioadhesive poly- mer to the formulation gave uniform release of drug while formulation without bioadhesive polymer showed irregular drug release pattern. Increase in concentration of bioadhesive polymers resulted in a decreased drug release. Comparison between formulations F5, F8 and F9 showed that PVP K 30 gave a better in vitro drug release than Carbopol 934 and Gelatin. Formulation containing Carbopol 934 fails to comply weight variation test due to its stickiness and improper die filling. Formulation containing gelatin though gave satisfactory in vitro drug release but residue remained after complete dissolution, which could give an unpleasent mouth feel.
Optimization of prepared sublingual tablet
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In the present work formulation Nos. 1 to 11 were tabulated in historical data mixture design 8.0.7.1(Trial Version) and based on numerical optimization the global best formulation (best values of excipients) was determined. In a mixture design, the level of a single component cannot be changed independently and the sum of the mixture components has to be equal to 100%. Ondansetron HCl (5 mg) tablets were prepared with a constant weights of various excipients like magnesium stearate (1.25 mg), talc (6.25 mg) and Sodium saccharine (0.312 mg)and the total tablet weight was kept constant (125 mg). Therefore, the experimental range lies between 0 and 112.185 mg. The restrictions imposed on the mixture component proportions are shown in (Table 7) . Experimental ranges were applied in order to comply with the relevant amounts of the same actually utilized in commercial pharmaceutical formulations. Dependent variables considered in this study were hardness, disintegration time, wetting time, % drug release, first order release kinetic, weight variation & content uniformity which are shown in (Table 8) . along with their acceptable ranges for a sublingual tablet. The formulations prepared were evaluated for precompression and post compression parameters. The data obtained was analyzed using linear model of design expert 8.0.7.1(Trial version). The response contour plots predicted from the linear model for dependent variable are shown in (Table 2-5) .
Historical data mixture optimization results
The aim of the optimization was to attain the defined targets for all responses simultaneously with respect to the predefined constraints. At this stage, the defined desirable areas of all responses were superimposed and the region of interest was generated. Three formulations with high desirability were suggested in this procedure by Design expert 8.0.7.1 (Trial Version). The suggested formulations are given in Table 9 . The overlay plot for three formulations suggested in optimization procedure is shown in Figure 6 . 
SUMMARY AND CONCLUSION
The sublingual tablet containing Ondansetron HCl as a model antiemetic agent was formulated by direct compression technique using mannitol coprocessed with maltose corn starch and optimized using Historical data mixture design 8.0.7.1(Trial Version). Based upon the results obtained it was concluded that coprocessing of low compressible saccharides with high compressible saccharides improves precompression as well as postcompression characters of tablet such as flow property, compressibility, hardness, disintegration and in vitro drug release. Mannitol:Maltose:Cornstarch in ratio of 19:2:1 exhibited ideal sublingual tablet characteristics. Study on effect of superdisintegrants on tablet formulation proved that the use of crospovidone in a concentration of 4% gave tablets with disintegration time of less than 80 seconds while drug release of more than 80 % after 15 minutes of in vitro dissolution studies was observed. Addition of bioadhesive polymer into formulation helps to release the drug uniformly over period of 20 minutes. In case of prepared tablet, PVP K 30 in a concentration of 0.5% exhibited better in vitro drug release. Based on results of Optimization studies Formulation B prepared by using coprocessed excipient of mannitol:maltose:corn starch in ratios of 19:2:1 was adjudged as global best formulation as it established good correlation between predicted and observed values for response.
